Evidence map›Paper›PMID 30657737›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study.

Ching-Hon Pui, Paola Rebora, Martin Schrappe, Andishe Attarbaschi, Andre Baruchel, Giuseppe Basso, Hélène Cavé, Sarah Elitzur, Katsuyoshi Koh, Hsi-Che Liu and 9 more

Registry-linked trialAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00137111 (Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00137111 phase3completednot on this map

Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan2000 to 2014Enrolled501ConditionsLymphoblastic Leukemia, AcuteArmsPrednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. HemaSphere · 2025
    Article
  5. Review
  6. Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Review
  7. Article
  8. Article
  9. Overview on Aneuploidy in Childhood B-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 12 countries.

Ching-Hon Pui1 St Jude Children's Research Hospital and University of Tennessee Health Science Center, Memphis, TN.
Paola Rebora2 University of Milano-Bicocca, Monza, Italy.
Martin Schrappe3 University of Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Andishe Attarbaschi4 St Anna's Children's Hospital and Medical University of Vienna, Vienna, Austria.
Andre Baruchel5 Robert Debré Hospital and Paris Diderot University, Paris, France.
Giuseppe Basso6 University of Padova, Padova, Italy.
Hélène Cavé5 Robert Debré Hospital and Paris Diderot University, Paris, France.
Sarah Elitzur7 Tel Aviv University, Tel Aviv, Israel.
Katsuyoshi Koh8 Saitama Children's Medical Center, Saitama, Japan.
Hsi-Che Liu9 MacKay Memorial Hospital, Taipei, Taiwan.
Kajsa Paulsson10 Lund University, Lund, Sweden.
Rob Pieters11 Princess Máxima Centre for Pediatric Oncology, Utrecht, the Netherlands.
Lewis B Silverman12 Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA.
Jan Stary13 University Hospital Motol and Charles University, Prague, Czech Republic.
Ajay Vora14 Great Ormond Street Hospital, London, United Kingdom.
Allen Yeoh15 National University of Singapore, Singapore.
Christine J Harrison16 Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom.
Maria Grazia Valsecchi2 University of Milano-Bicocca, Monza, Italy.
Ponte di Legno Childhood ALL Working Group
Délégation Paris 7 · FRUniversity of Milano-Bicocca · ITBoston Children's Hospital · USCharles University · CZLund University · SEMackay Memorial Hospital · TWNational University of Singapore · SGNewcastle University · GBPrincess Máxima Center · NLSaitama Children's Medical Center · JPSt Anna Children's Hospital · ATTel Aviv University · ILUniversity College London · GBUniversity of Padua · ITUniversity of Tennessee Health Science Center · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)R37CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1987 to 2014
$9.7M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
Pharmacogenomics of Childhood Leukemia ALLR01CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1985 to 2019
$3.6M
ARID5B and disparities of childhood leukemiaU01CA176063 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YANG, JUN J. · 2014 to 2018
$2.4M
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA036401NCI NIH HHS R37 CA036401NCI NIH HHS U01 CA176063NIGMS NIH HHS U01 GM092666
6 · The paper itself

Abstract

purposeWe determined the prognostic factors and utility of allogeneic hematopoietic cell transplantation among children with newly diagnosed hypodiploid acute lymphoblastic leukemia (ALL) treated in contemporary clinical trials. PATIENTS AND

methodsThis retrospective study collected data on 306 patients with hypodiploid ALL who were enrolled in the protocols of 16 cooperative study groups or institutions between 1997 and 2013. The clinical and biologic characteristics, early therapeutic responses as determined by minimal residual disease (MRD) assessment, treatment with or without MRD-stratified protocols, and allogeneic transplantation were analyzed for their impact on outcome.

resultsWith a median follow-up of 6.6 years, the 5-year event-free survival rate was 55.1% (95% CI, 49.3% to 61.5%), and the 5-year overall survival rate was 61.2% (95% CI, 55.5% to 67.4%) for the 272 evaluable patients. Negative MRD at the end of remission induction, high hypodiploidy with 44 chromosomes, and treatment in MRD-stratified protocols were associated with a favorable prognosis, with a 5-year event-free survival rate of 75% (95% CI, 66.0% to 85.0%), 74% (95% CI, 61.0% to 89.0%), and 62% (95% CI, 55.0% to 69.0%), respectively. After exclusion of patients with high hypodiploidy with 44 chromosomes and adjustment for waiting time to transplantation and for covariables in a Poisson model, disease-free survival did not differ significantly ( P = .16) between the 42 patients who underwent transplantation and the 186 patients who received chemotherapy only, with an estimated 5-year survival rate of 59% (95% CI, 46.5% to 75.0%) versus 51.5% (95% CI, 44.7% to 59.4%), respectively. Transplantation produced no significant impact on outcome compared with chemotherapy alone, especially among the subgroup of patients who achieved a negative MRD status upon completion of remission induction.

conclusionMRD-stratified treatments improved the outcome for children with hypodiploid ALL. Allogeneic transplantation did not significantly improve outcome overall and, in particular, for patients who achieved MRD-negative status after induction.

Indexed as

DiploidyHematopoietic Stem Cell TransplantationAdolescentAge FactorsAntineoplastic AgentsChildChild, PreschoolClinical Trials as TopicFemaleHumansMaleNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaProgression-Free SurvivalRetrospective StudiesTime FactorsAntineoplastic Agents

Identifiers

PMID30657737
PMCPMC7051863
OpenAlexW2909902955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.